UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~ 10June 30, 2015

TRISTAR WELLNESS SOLUTIONS, INC. (Exact name of registrant as specified in its charter)

Nevada		000-29981		91-2027724
(State or other jurisdiction of incorporation)		(~~CommissionFile~~Commission File Number)		(I.R.S. Employer Identification No.)

10 Saugatuck Ave. ~~Westport CT 06880 (Address of principal executive offices) (zip code)~~

~~(203)~~Westport ~~226-4449~~CT ~~(Registrant’s telephone number, including area code)~~06880

(~~Former~~Address ~~name~~of orprincipal ~~former~~executive ~~address,~~offices) if(zip ~~changed since last report.~~code)(203) 226-4449

(Registrant's telephone number, including area code)

______________________________________________
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

¨Section ~~Soliciting~~5 ~~material pursuant to Rule 14a~~-12- ~~under~~Corporate ~~the~~Governance ~~Exchange~~and ~~Act (17 CFR 240.14a-12)~~Management

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 5 – Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

1. On February 10, 2015, Mr. John R. Linderman resigned his positions as our Chief Executive Officer, President and as a member of our Board of Directors. Mr. Linderman did not hold any positions on any Board committees at the time of his resignation. We are not aware of any disagreements Mr. Linderman had with us required to be disclosed under this Item. We will (i) provide Mr. Linderman with a copy of this disclosure in Item 5.02 the same day we file this Form 8-K with the Commission; and (ii) provide Mr. Linderman with the opportunity to furnish us as promptly as possible with a letter addressed to us stating whether he agrees with the statements made by us in response to this Item 5.02 and, if not, stating the respects in which he does not agree; and (iii) file any letter received by us from Mr. Linderman with the Commission as an exhibit by an amendment to this Form 8-K within two business days after receipt by us. 2. On February 13, 2015, our Board of Directors appointed Mr. Michael Wax, our current Chief Development Officer and a member of our Board of Directors, to the position of interim Chief Executive Officer (our Principal Executive Officer). Mr. Wax is not related to any of our current officers or directors by family or marriage. Our Board of Directors will be conducting a search for a permanent Chief Executive Officer and we plan to hire a permanent Chief Executive Officer as soon as possible.

1.	On June 30, 2015, Mr. Frederick A. Voight resigned his positions as our Chief Investment Officer and as a member of our Board of Directors. Mr. Voight did not hold any positions on any Board committees at the time of his resignation. We are not aware of any disagreements Mr. Voight had with us required to be disclosed under this Item. We will (i) provide Mr. Voight with a copy of this disclosure in Item 5.02 the same day we file this Form 8-K with the Commission; and (ii) provide Mr. Voight with the opportunity to furnish us as promptly as possible with a letter addressed to us stating whether he agrees with the statements made by us in response to this Item 5.02 and, if not, stating the respects in which he does not agree; and (iii) file any letter received by us from Mr. Voight with the Commission as an exhibit by an amendment to this Form 8-K within two business days after receipt by us.

2.	On June 30, 2015, our Board of Directors appointed Michel Boileau, M.D. and Stuart Sands as members of our Board of Directors, effectively immediately, to serve until the next annual meeting of our shareholders or until their successors have been elected and qualified, or until they resign or are removed.

~~Michael~~Michel ~~Wax is our interim Chief Executive Officer~~Boileau, ~~our~~M.D. ~~Chief~~has ~~Development~~been ~~Officer and~~ a member of our Board of Directors. Hesince ~~began~~June ~~his~~30, ~~professional~~2015. ~~career~~Dr. inBoileau ~~New~~is ~~York~~a ~~City~~board atcertified ~~CBS~~urologist ~~Inc.~~and asexperienced aphysician ~~key~~executive. ~~member~~From of2011 athrough ~~small~~2014, ~~team~~Dr. ofBoileau ~~international~~served ~~strategic~~as ~~planning~~the ~~executives~~Chief ~~responsible~~Clinical Officer for ~~acquiring,~~St. ~~divesting~~Charles ~~and~~Health ~~operating international divisions~~System, a ~~position~~four hehospital ~~held~~system, ~~from~~with ~~1978~~350 tobeds ~~1981.~~and ~~While~~approximately ~~there~~3,000 heemployees, ~~helped~~serving tocentral ~~complete~~and ~~numerous~~eastern ~~multinational~~Oregon. ~~transactions~~In ~~across~~this arole ~~wide~~he ~~array~~developed ofa ~~businesses~~strong background in ~~the~~patient ~~communications~~safety ~~industry.~~and ~~In 1981~~quality, heas ~~joined~~well ~~American~~as ~~Express~~clinical ~~and~~integration, ~~continued~~joint ~~his~~ventures ~~trans-Atlantic business development career~~ with ~~specific~~external ~~responsibilities~~partners, ~~for~~physician ~~coordinating~~engagement, ~~administration~~ and ~~operational~~interprofessional ~~tasks~~education ~~with acquisitions~~ and ~~divestments~~research. ~~Mr.~~Additionally, ~~Wax~~he ~~began~~assisted ~~his career~~ in ~~the~~setting ~~greater~~up ~~Boston~~education ~~area by founding Wax & Company~~ and/or ~~Avatar~~research ~~Securities~~partnerships ~~Corporation,~~with athe ~~boutique~~two ~~investment~~medical ~~banking~~schools ~~concern~~in ~~focused~~Oregon onand ~~mid-cap transactions primarily~~ with ~~medical~~Oregon ~~technology~~State ~~innovations~~University. MrCurrently, Dr. ~~Wax~~Boileau ~~was~~is the ~~firm’s~~Senior ~~listed~~Administrative ~~principal~~Advisor ~~with~~to ~~the~~St. ~~SEC~~Charles ~~for~~Health ~~this registered broker/dealer~~System. ~~Mr.~~From ~~Wax~~2009 ~~personally~~through ~~held FINRA security licenses Series 27~~2011, ~~Financial~~Dr. &Boileau ~~Operations~~was ~~Principal,~~on ~~Series~~the ~~24,~~founding ~~General~~committee ~~Security Principal,~~ and ~~Series~~was 7Chair &of ~~63,~~Physician ~~General~~Hospital ~~Security~~Alignment ~~Representative.~~of ~~Avatar~~Central ~~provided equity and debt capital formation~~Oregon, ~~strategic~~where ~~consulting~~he ~~and~~led ~~mergers~~the ~~and~~hospital ~~acquisition~~system ~~transaction~~reorganization ~~services~~with asa ~~well~~focus ason ~~valuations~~clinical integration and ~~fairness~~enhanced ~~opinions.~~physician ~~In 1996 Mr~~engagement. ~~Wax~~From ~~moved~~1987 tothrough ~~Bend~~2014, ~~Oregon and co-founded DesChutes Medical Products, Inc~~Dr., ~~where~~Boileau asmanaged ~~President~~a ~~and~~community ~~CEO~~urology hemedical ~~guided~~practice, ~~the~~including ~~company~~being ~~from~~ the ~~patent~~managing ~~formation~~partner ~~stage,~~of ~~through~~Bend ~~commercial~~Urology ~~product~~Associates ~~launch~~from ~~and~~1991 to ~~complete~~2011. ~~divestment~~Dr. ~~During~~Boileau received his ~~tenure~~Bachelor atof ~~DesChutes~~Arts he(Biology) ~~successfully~~from ~~initiated~~Whitman anCollege ~~international~~in ~~distribution~~1969, ~~strategy~~received ashis ~~well~~Doctor ~~introducing~~of ~~OTC~~Medicine ~~products~~from toOregon ~~the~~Health ~~domestic~~Sciences ~~retail~~University ~~markets.~~in ~~Numerous~~1973, ~~products~~served ~~were~~his ~~developed~~internship ~~and~~in ~~harvested~~internal tomedicine ~~larger~~at ~~medical~~Northwestern ~~companies.~~Memorial InHospital ~~early~~from ~~2009~~1973-1974, ~~DesChutes~~served ~~was~~his ~~sold~~residency toin ~~Jarden~~urology ~~Corporation~~at ~~(JAH:NYSE).~~Oregon ~~Several~~Health ~~months~~Sciences ~~later~~University hefrom co1974-~~founded All Green Capital~~1979, ~~LLC,~~and aserved ~~structured~~his ~~finance~~fellowship ~~consulting~~in ~~concern~~urologic ~~with~~oncology ~~specific~~at ~~focus on structured finance of renewable energy projects and companies~~M. MrD. ~~Wax~~Anderson ~~holds~~Tumor aInstitute ~~graduate degree~~ from ~~the~~1979-1980. ~~University of Chicago~~Dr. HeBoileau's ~~has~~extensive ~~been~~experience ain ~~founding~~the ~~board~~healthcare ~~member and Chairman of Oregon State University~~field, ~~Cascades~~as ~~Campus~~well ~~and~~as ~~presently~~his ~~sits~~experience onin ~~the~~managerial ~~strategic~~positions, ~~planning~~makes ~~board~~him ofan ~~St.~~ideal ~~Charles~~Director ~~Medical~~for ~~Center~~our ~~in Bend, Oregon~~company.

MrWe have a Consulting Services Agreement with Dr. ~~Wax~~Boileau, ~~does~~entered ~~not~~into ~~own~~on ~~any~~March ~~shares~~5, of2015, ~~common~~under ~~stock~~which ~~but~~Dr. ~~owns~~Boileau ~~warrants~~provides support and information to ~~purchase~~HemCon's ~~550~~senior executive officers regarding expanding current products,~~000~~ new product development and present medical practices/healthcare policies. In exchange for Dr. Boileau's services under the agreement, we issued him warrants to purchase shares of our common stock, atwhich ~~$1.00~~warrants ~~per~~are ~~share~~exercisable immediately and expire on April 7, 2019. ~~Currently~~Dr. Boileau does not own any of our shares or other securities, Mrexcept the warrants listed herein. ~~Wax~~Dr. Boileau is not ~~compensated~~currently ~~for~~receiving ~~his~~any ~~services~~compensation for serving as a member of our Board of Directors.

3.Stuart OnSands ~~February~~has ~~13,~~been ~~2015,~~a ~~our~~member ~~Board~~ of ~~Directors appointed Mr. Harry Pond to serve on~~ our Board of Directors tosince ~~fill~~June ~~the~~30, ~~vacancy left by Mr~~2015. ~~Linderman’s resignation.~~ Mr. ~~Pond~~Sands ~~will~~is ~~serve as a Director until~~ the ~~next~~Chief ~~annual~~Financial ~~meeting~~Officer and ~~his~~Chief ~~successor~~Operating isOfficer ~~duly~~at ~~elected~~HemCon ~~and~~Medical ~~qualified~~Technologies, ~~or until his earlier resignation or removal~~Inc., ~~Harry Pond is a member of~~ our ~~Board~~wholly-owned ~~of Directors~~subsidiary. ~~From 2005 to present,~~ Mr. ~~Pond~~Sands ~~has~~joined ~~served~~HemCon ~~as Managing Director of Rockland Group, LLC, which is a real estate development company active~~ in ~~the Houston, Texas real estate market. From~~ 2008 ~~to present, Mr. Pond has served as a senior business executive for Rockland Insurance Agency, Inc. In this position he is actively involved~~ with the ~~management~~acquisition of ~~loss~~the ~~prevention,~~Irish ~~marketing,~~medical ~~and~~device ~~recruiting to ensure the~~ company’s ~~profitability~~Alltracel ~~and~~Pharmaceuticals ~~productivity~~Plc. ~~From~~Prior ~~1979~~ to ~~present,~~his ~~Mr.~~appointment ~~Pond~~as ~~has~~Chief ~~owned~~Operating ~~and operated The Harry Pond Insurance Agency~~Officer, ~~a company that he is currently in the process of merging with Rockland Insurance Agency, Inc.~~ Mr. ~~Pond~~Sands ~~also~~operated ~~serves~~solely onas the ~~Board of Directors of InterCore, Inc. (ICOR), a~~ company's ~~currently~~Chief ~~quoted~~Financial ~~on OTC Markets~~Officer. Mr. ~~Pond~~Sands ~~received~~has ~~his BS in mathematics and education from Texas State University. 4. On February 12~~been, ~~2015, Mr. James (Jamie) H. Barickman resigned his positions as our Chief Marketing Officer~~ and ascontinues a member of our Board of Directors. Mr. Barickman did not hold any positions on any Board committees at the time of his resignation. We are not aware of any disagreements Mr. Barickman had with us required to be, ~~disclosed~~instrumental ~~under this Item. We will (i) provide Mr. Barickman with a copy of this disclosure~~ in ~~Item~~all ~~5.02~~corporate ~~the~~finance ~~same~~initiatives ~~day~~at weHemCon, ~~file~~including ~~this~~capitalizing ~~Form~~on ~~8-K~~maximizing ~~with~~asset ~~the~~realization ~~Commission;~~ and ~~(ii) provide Mr. Barickman with~~ the ~~opportunity~~acquisition toof ~~furnish~~HemCon ~~us as promptly as possible with a letter addressed to us stating whether he agrees with the statements made~~ by us in ~~response~~May ~~to this Item 5~~2013.02 ~~and, if not, stating the respects in which he does not agree; and (iii) file any letter received by us from~~ Mr. ~~Barickman~~Sands ~~with~~has ~~the~~executed ~~Commission~~numerous asM&A antransactions ~~exhibit~~during byhis antenure ~~amendment to this Form 8-K within two business days after receipt by us. 5. In connection~~ with ~~the~~Alltracel ~~management~~Pharmaceutical ~~changes at TriStar Wellness Solutions, Inc~~Plc., weBefore ~~have~~joining ~~also appointed key personnel at our subsidiary,~~ HemCon ~~Medical Technologies~~, ~~Inc.,~~he toworked ~~support~~for ~~completing~~Global ~~the transition to exclusively focus the company’s resources on marketing and sales~~Enterprises, ~~new~~Ernst ~~product development~~ and ~~technological~~Young ~~innovations, best of class regulatory~~ and ~~quality~~Tesco ~~systems~~Plc. ~~HemCon~~Mr. ~~has~~Sands ~~successfully~~received ~~completed~~his ~~their~~Bachelor's ~~physical~~degree ~~move to new facilities~~ in ~~downtown~~Accounting ~~Portland, Oregon~~ and ~~transferred~~Finance ~~all~~from ~~manufacturing~~Dublin toCity ~~U.S. based world class outsourcing partners. As part of these new appointments~~University, ~~Simon~~in ~~McCarthy~~Dublin, ~~formerly~~Ireland ~~the~~and ~~Chief~~he ~~Scientific~~is ~~Officer~~also ata ~~HemCon,~~Fellow ~~has~~of ~~been promoted to~~ the ~~new~~Institute ~~position~~ of ~~Science~~Chartered ~~and~~Accountant ~~Technology~~in ~~Fellow~~Ireland at(FCA). ~~HemCon,~~He ~~Stuart~~is ~~Sands,~~ currently ~~HemCon’s~~completing ~~Chief~~a ~~Financial~~Master's ~~Officer~~in ~~has~~Business ~~also~~Administration ~~been~~from ~~appointed~~Babson toCollege, ~~the~~in ~~position of Chief Operating Officer~~Wellesley, DrMA. ~~Brian~~Mr. ~~Clare,~~Sands' ~~Senior~~more ~~Scientist~~than at15 ~~HemCon~~years ~~has~~of ~~been~~experience ~~promoted~~in tofinance ~~Vice~~gained ~~President~~both ofthrough ~~Innovation,~~public accounting and ~~Dr.~~in ~~Maire~~the Niindustry ~~Beilliu,~~makes ~~has~~him ~~been~~an ~~promoted~~ideal toDirector ~~Vice~~for ~~President~~our ~~of Regulatory Affairs & Quality Systems~~company.

3Mr. Sands does not own any of our shares or other securities. Mr. Sands is not currently receiving any compensation for serving as a member of our Board of Directors.

Section 98 –-- ~~Financial~~Other ~~Statements and Exhibits~~Events

Item 98.01 ~~Financial~~-- ~~Statements~~Other ~~and Exhibits~~Events

On July 1, 2015, we agreed to sell all of our assets related to the Beaute de Maman (c"BDM") ~~Exhibits~~product line, which is a line of skincare and other products specifically targeted for pregnant and nursing women, to Intelero Corp., a company unrelated to our company. As stated in our most recent Annual Report on Form 10-K, we have not been focusing our resources on the BDM product line and did not plan to do so for the foreseeable future. Under the agreement to sell the assets related to the BDM product line, in exchange for the assets we are receiving a One Hundred Fifty Thousand ($150,000) principal amount promissory note at eight percent (8%) interest that matures in twenty-four (24) months and is secured by the BDM product line assets.

10.1	Employment Agreement with Michael Wax.
99.1	Press release dated February 17, 2015 issued by TriStar Wellness Solutions, Inc. c., announcing management changes at HemCon Medical Technologies, Inc.

4SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TriStar Wellness Solutions, Inc. a Nevada corporation

Dated: July 7, 2015	By:	/s/ Michael Wax
	Name:	Michael Wax
	Its:	Interim Chief Executive Officer

	TriStar Wellness Solutions, Inc.
	a Nevada corporation
Date: February 17, 2015	By:	/s/ Michael Wax
		Michael Wax
	Its:	Interim Chief Executive Officer

Filing Compare · TRISTAR WELLNESS SOLUTIONS, INC.